01344nas a2200421   4500000000100000000000100001000000100002008004100003653001100044653006400055653000900119653001100128653003200139653005600171653001600227653004700243653001000290653006700300653004900367653006800416653004800484653000900532653003200541653002000573653001700593653003100610653002300641100001600664700001500680700001200695700001400707700001500721700001600736245011700752250001500869490000700884020003100891       2024                            d10aHumans10a*Influenza Vaccines/administration & dosage/adverse effects10aMale10aFemale10aUnited Kingdom/epidemiology10a*Influenza, Human/prevention & control/epidemiology10aMiddle Aged10a*Inflammatory Bowel Diseases/complications10aAdult10a*Vaccines, Inactivated/administration & dosage/adverse effects10aVaccine Efficacy/statistics & numerical data10aVaccination/statistics & numerical data/adverse effects/methods10aHospitalization/statistics & numerical data10aAged10aProportional Hazards Models10aCrohn's colitis10aepidemiology10ainflammatory bowel disease10aulcerative colitis1 aG. Nakafero1 aM. Grainge1 aT. Card1 aC. Mallen1 aJ. Van-Tam1 aA. Abhishek00aUptake, safety and effectiveness of inactivated influenza vaccine in inflammatory bowel disease: a UK-wide study  a2024/06/200 v11  a2054-4774 (Print)2054-4774